Modality
Bispecific Ab
MOA
C5i
Target
USP1
Pathway
Angiogenesis
HS
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
Aug 2022
→ May 2029
Phase 1Current
NCT08047461
1,563 pts·HS
2022-08→2029-05·Recruiting
1,563 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-05-093.1y awayPh2 Data· HS
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2029-05-09 · 3.1y away
HS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08047461 | Phase 1/2 | HS | Recruiting | 1563 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Tezesotorasib | Enliven | Phase 2 | USP1 | |
| ETN-5063 | 89bio | Phase 1/2 | USP1 | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C | |
| MD-IIT-621 | MD Anderson | Phase 2/3 | USP1 | |
| GUS-IIT-951 | Gustave Roussy | Approved | USP1 | |
| SWO-IIT-148 | SWOG | Approved | USP1 |